Full Press Release Details
Inspira Technologies Reports First Half
2025 Financial Results and Issues Business Update
Inspira delivered major milestones throughout
and following the six months ended June 30, 2025, including the receipt of $49.5 million in binding purchase orders, clinical validation
in leading hospitals, 97.35% accuracy for its HYLA blood sensor, and strategic patent protection, underscoring accelerating commercial
RA'ANANA, Israel, October 1, 2025 -- Inspira Technologies
OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic
technologies, today announced its financial results for the six-month period ended June 30, 2025, and issued a business update.
"The first half of 2025 represents a pivotal
transformation for Inspira as we have successfully transitioned from being a development-stage company to commencing commercial execution.
Our technology is now saving lives in premier U.S. hospitals while generating growing commercial interest globally," said Dagi
Ben-Noon, Chief Executive Officer of Inspira. "With $49.5 million in binding purchase orders secured and clinical validation at
leading medical institutions, including for complex lung transplant procedures, we are witnessing the accelerated adoption of our breakthrough
platform. Our HYLA blood sensor's 97.35% accuracy results position us well for our planned U.S. Food & Drug Administration
("FDA") submission and further strengthens our outlook. As we are in position to scale manufacturing to meet this confirmed
global demand, driven by the fulfillment of these orders and our expanding pipeline, we are targeting an annual revenue run rate of at
least $70 million in 2026. To ensure we fully
capitalize on this momentum, we have also engaged a leading strategic advisory firm to help guide our execution and unlock further avenues
for growth, reinforcing our position as a transformative force in advanced respiratory care."
Recent Business and Operational Updates:
Financial Results for the Six Months Ended June
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing
in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. Food and Drug Administration -cleared
INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures
outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation
while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA , a proprietary blood sensor
platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining
of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape.
The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector
collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
For more information, visit: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied
forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations
of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when
it discusses the benefits and advantages of its technology and devices, its belief that its HYLA blood sensor's accuracy results
position it well for its FDA submission and strengthens its outlook, its targeted annual revenue run rate and timing thereof, its expectation
to recognize revenues and timing thereof, and the belief that its engagement with a strategic advisory firm will unlock further avenues
for growth and reinforce its position as a transformative force in advanced respiratory care. These forward-looking statements and their
implications are based solely on the current expectations of the Company's management and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as
otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's
annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the
"SEC"), which is available on the SEC's website at www.sec.gov.
Inspira Technologies - Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Arx Investor Relations
North American Equities Desk
STATEMENTS OF BALANCE SHEETS
(US dollars in thousands)
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | 2,126 | 5,111 | ||||||
| Cash deposits | - | 668 | ||||||
| Other accounts receivable | 418 | 587 | ||||||
| Inventory | 711 | 444 | ||||||
| Total current assets | 3,255 | 6,810 | ||||||
| Non-Current Assets: | ||||||||
| Right of use assets, net | 670 | 761 | ||||||
| Property, plant and equipment, net | 527 | 499 | ||||||
| Total non-current assets | 1,197 | 1,260 | ||||||
| Total Assets | 4,452 | 8,070 |
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Trade accounts payables | 170 | 154 | ||||||
| Other accounts payable | 1,478 | 1,364 | ||||||
| Lease liabilities | 292 | 277 | ||||||
| Financial Liabilities at Fair Value | 886 | 1,575 | ||||||
| Total current liabilities | 2,826 | 3,370 | ||||||
| Non-Current Liabilities: | ||||||||
| Lease liabilities | 348 | 378 | ||||||
| Total non-current liabilities | 348 | 378 | ||||||
| Shareholders' Equity: | ||||||||
| Share capital and additional paid in capital | 74,250 | 70,896 | ||||||
| Accumulated deficit | (72,972 | ) | (66,574 | ) | ||||
| Total equity | 1,278 | 4,322 | ||||||
| Total Liabilities and Shareholders' Equity | 4,452 | 8,070 |
STATEMENTS OF COMPREHENSIVE
(US dollars in thousands)
| Six months June 30, 2025 | Six months June 30, 2024 | |||||||
| Revenues | 289 | - | ||||||
| Cost of revenues | 287 | - | ||||||
| Gross Profit | 2 | - | ||||||
| Research and development expenses | 3,638 | 3,270 | ||||||
| General and administrative expenses | 3,150 | 2,182 | ||||||
| Sales and marketing expenses | 442 | 349 | ||||||
| Other expenses (income) | 7 | 5 | ||||||
| Operating loss | 7,235 | 5,806 | ||||||
| Interest Income from deposits | (37 | ) | (83 | ) | ||||
| Finance expenses (income), net | (800 | ) | 517 | |||||
| Loss before tax | 6,398 | 6,240 | ||||||
| Taxes on income | - | - | ||||||
| Total comprehensive loss for the period | 6,398 | 6,240 |
STATEMENTS OF CHANGES IN SHAREHOLDERS'
(US dollars in thousands)
For the six months ended June 30, 2025:
| Number of shares | Share capital and additional paid in capital | Accumulated deficit | Total | |||||||||||||
| Balance on January 1, 2025 | 24,252,096 | 70,896 | (66,574 | ) | 4,322 | |||||||||||
| Changes during the period: | ||||||||||||||||
| Issuance of ordinary shares and Pre-funded warrants, net | 2,575,753 | 1,508 | - | 1,508 | ||||||||||||
| Exercise of options | 81,633 | 8 | - | 8 | ||||||||||||
| Exercise of Pre-funded warrants | 658,372 | * | - | - | ||||||||||||
| Restricted share unit vesting | 1,083,443 | - | - | - | ||||||||||||
| Share-based compensation | - | 1,838 | - | 1,838 | ||||||||||||
| Comprehensive and net loss | - | - | (6,398 | ) | (6,398 | ) | ||||||||||
| Balance on June 30, 2025 | 28,651,297 | 74,250 | (72,972 | ) | 1,278 |
For More Financial Information:
For a comprehensive understanding of the Company's financial reports
and related management's discussion and analysis for applicable periods, please review the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2024, and the Company's Form 6-K containing the unaudited condensed consolidated financial statements for
the six months ended June 30, 2025, both available on the Company's EDGAR profile at https://www.sec.gov/edgar